Argos Therapeutics Reports Second Quarter 2015 Financial Results and Operational Highlights

- Independent Data Monitoring Committee (IDMC) Recommended Continuation of Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 -
- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 -
- Established Scientific Advisory Board -
- Conference Call and Webcast Today, August 12th, at 4:30 p.m. ET -

DURHAM, N.C., Aug. 12, 2015 -- Argos Therapeutics, Inc. (ARGS), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis(R) technology platform, today reported financial results for the second quarter ended June 30, 2015 and provided an update on the Company's clinical programs.

Published: 20 August 2015
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: Argos Therapeutics Inc ( ARGS )

Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce $75 Million Private Placement

NEW YORK, NY and LONDON, UNITED KINGDOM--(August 18, 2015) - Celsus Therapeutics Plc (CLTX) and Volution Immuno Pharmaceuticals SA today announced that Celsus has entered into a securities purchase agreement for a private placement with a select group of investors, led by Deerfield, and including Venrock, Vivo Capital, Foresite Capital, New Enterprise Associates, QVT Financial, RA Capital Management and certain other institutional investors.

The closing of the private placement is subject to Celsus obtaining shareholder approval of the financing transaction and the previously announced acquisition by Celsus of Volution Immuno Pharmaceuticals at Celsus' General Shareholder Meeting on September 16, 2015, the closing of the acquisition and satisfaction of customary closing conditions. Following the closing of the acquisition, the combined company will be renamed Akari Therapeutics Plc, and the company expects to trade on the NASDAQ Capital Market under the ticker symbol 'AKTX'.

Published: 19 August 2015
Written by Editor
Nasdaq   Up on News   Financing  
Read more: Celsus Therapeutics Plc ( CLTX )

Corbus Pharmaceuticals' Investigational Drug Resunab(TM) Granted Fast Track Status by the U.S. FDA for the Treatment of Systemic Sclerosis

NORWOOD, MA--( Aug 19, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and Drug Administration ("FDA") has designated as a Fast Track development program the investigation of Resunab™ for systemic sclerosis ("scleroderma").

Systemic sclerosis is a serious, life-threatening autoimmune disease that is characterized by chronic activation of the immune system, damage to blood vessels, and fibrosis (scarring) of the skin, lungs, and other internal organs. Systemic sclerosis affects predominately women in mid-life and is associated with significant morbidity and mortality. There are currently no FDA-approved drug therapies for systemic sclerosis.

Published: 19 August 2015
Written by Editor
Nasdaq   FDA HC Decision   Up on News  
Read more: Corbus Pharmaceuticals Holdings Inc ( CRBP )

Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001

SOLANA BEACH, Calif., Aug. 18, 2015 -- Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating the agency's concurrence with the Company's proposed pediatric study plan for EVK-001.

Pursuant to the terms of the letter, the FDA has accepted Evoke's EVK-001 pediatric study plan, which included a request for a full waiver of the requirement to conduct pediatric studies on the basis that diabetic gastroparesis is an adult disease. The Company expects that the pediatric study plan will be included in the Company's anticipated New Drug Application (NDA) filing with the FDA.

Published: 18 August 2015
Written by Editor
Nasdaq   FDA HC Decision   Up on News  
Read more: Evoke Pharma Inc ( EVOK )

Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial

-- Company Plans for Phase 3 Program Based on Consistent Response in TMA Patients --

SEATTLE, Aug. 18, 2015  -- Omeros Corporation (OMER) today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of TMAs, including atypical hemolytic uremic syndrome (aHUS).

Published: 18 August 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Omeros Corporation ( OMER )
  1. AVEO Oncology ( AVEO )
  2. Onconova Therapeutics Inc ( ONTX )
  3. Galectin Therapeutics Inc ( GALT )
  4. Enzymotec Ltd ( ENZY )
  5. Eleven Biotherapeutics Inc ( EBIO )